Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs CarMax, Inc (KMX) Price & Performance

AbCellera Biologics IncTrade
CarMax, IncTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs CarMax, Inc — how do they compare? AbCellera Biologics Inc trades at $9.92 (market cap $2.99B), while CarMax, Inc trades at $58.26 (market cap $8.26B). The key difference: CarMax, Inc is far larger — about 2.8× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, CarMax, Inc nearer its low. Which is the better fit depends on your goals.

ABCLKMX
Market Cap
$2.99B$8.26B
Sector
HealthConsumer Cyclical
52-Week High
$9.76$62.17
52-Week Low
$2.78$30.88
Enterprise Value
$2.58B$26.77B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.

The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.

CarMax, Inc

CarMax (KMX) trades at $58.20, showing modest near-term weakness with a 0.99% daily decline. The stock maintains a bullish technical stance with strong moving average support and trades near key support at $58. Fundamentally, the company reported Q1 2026 earnings beat with $0.34 EPS versus $0.23 expected, though revenue trends show slight contraction from $26.4B in 2025 to projected $26.3B in 2026. Recent positive developments include AI partnership enhancements and strong institutional recognition.

CarMax presents a mixed investment case with technical strength offset by fundamental challenges. The bullish moving average configuration and recent earnings beats provide near-term support, but declining revenue trends and thin 0.84% net margin limit upside potential. Key risks include ongoing fiduciary investigations and competitive pressure in the used car market. Analyst consensus remains cautious with 68.6% hold ratings and $53.09 price target below current levels.

Returns comparison

Trailing returns across standard periods

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About CarMax, Inc

CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.

Read more on KMX